We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
163 hedge funds and large institutions have $96.6M invested in Esperion Therapeutics in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 57 increasing their positions, 39 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
46% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 39
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7.87% less ownership
Funds ownership: 57.41% → 49.55% (-7.9%)
12% less funds holding
Funds holding: 186 → 163 (-23)
44% less capital invested
Capital invested by funds: $171M → $96.6M (-$74.9M)
61% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 36
68% less call options, than puts
Call options by funds: $242K | Put options by funds: $768K
Holders
163
Holders Change
-23
Holders Change %
-12.37%
% of All Funds
2.15%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
14
Increased
57
Reduced
39
Closed
36
Calls
$242K
Puts
$768K
Net Calls
-$526K
Net Calls Change
+$336K
Top Buyers
Top Sellers
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$14M |
| 2 |
Morgan Stanley
New York
|
-$5.54M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.67M |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$1.54M |
| 5 |
JP Morgan Chase
New York
|
-$1.36M |
